Research Article
Prevalence and Prognosis of Portopulmonary Hypertension in 223 Liver Transplant Recipients
Table 1
Demographic and clinical features of all included patients.
| | Variable | PoPH | Non-PoPH | |
| | Age (years) | 53.1 ± 8.7 | 50.6 ± 8.9 | 0.31 | | Gender (male/female), | 7/7 | 163/46 | 0.03 (Fisher) | | Etiology of liver disease, (%) | | | 0.28 (Fisher) | | HBV infection | 8 (57.1) | 153 (73.2) | — | | HCV infection | 1 (7.1) | 9 (4.3) | — | | Autoimmune hepatitis | 2 (14.3) | 17 (8.1) | — | | Alcoholic | 0 (0) | 10 (4.8) | — | | Others | 3 (21.4) | 20 (9.6) | — | | With hepatocellular carcinoma, (%) | | | 0.152 | | Yes | 4 (28.6) | 101 (48.3) | — | | No | 10 (71.4) | 108 (51.7) | — | | Cirrhosis, | | | 0.364 | | Yes | 12 | 191 | — | | No | 2 | 18 | — | | Ascites, | | | 0.249 | | Yes | 7 | 70 | — | | No | 7 | 139 | — | | Portal hypertension, | | | 0.001 | | Yes | 14 | 115 | — | | No | 0 | 94 | — | | Child–Pugh score | 9 (6–11) | 7 (5–12) | 0.001 | | MELD | 20.5 (8–31) | 12 (6–40) | 0.006 | | CO (L/min) | 6.9 ± 2.8 | 6.1 ± 1.8 | 0.27 | | ALT (IU/L) | 35.5 (4–290) | 31.5 (6–652) | 0.54 | | AST (IU/L) | 78 (13–1098) | 46.9 (15.5–602) | 0.02 | | TBIL (mg/dL) | 6.9 (1.1–37.9) | 2.1 (0.2–54.6) | 0.005 | | Creatinine (mg/dL) | 0.7 (0.4–1.3) | 0.7 (0.3–80.4) | 0.29 | | ALB (g/L) | 30.1 ± 4.5 | 34.4 ± 6 | 0.01 | | Hb (g/L) | 85.1 ± 17.9 | 109.8 ± 25.5 | <0.001 |
|
|
HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, Model for End-Stage Liver Disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; ALB, albumin; Hb, hemoglobin.
|
